Search Results

Predictive and prognostic effect of ABO blood group on immune checkpoint inhibitors.

• Authors : Ergun Y; Department of Medical Oncology, Batman Training and Research Hospital, Batman, Turkey.; Esen SA

Subjects: Immune Checkpoint Inhibitors* ; Melanoma*/Melanoma*/Melanoma*/pathology; ABO Blood-Group System/ABO Blood-Group System/ABO Blood-Group System/therapeutic use

• Source: Cancer biomarkers : section A of Disease markers [Cancer Biomark] 2022; Vol. 34 (2), pp. 329-336.Publisher: IOS Press Country of Publication: Netherlands NLM ID: 101256509 Publication Model: Print Cited Medium:

Record details

The association between albumin-globulin ratio (AGR) and survival in patients treated with immune checkpoint inhibitors.

• Authors : Guven DC; Hacettepe University Cancer Institute, Ankara, Turkey.; Aktepe OH

Subjects: Globulins* ; Immune Checkpoint Inhibitors*; Cohort Studies

• Source: Cancer biomarkers : section A of Disease markers [Cancer Biomark] 2022; Vol. 34 (2), pp. 189-199.Publisher: IOS Press Country of Publication: Netherlands NLM ID: 101256509 Publication Model: Print Cited Medium:

Record details

Blockade of PD-1 and CTLA-4: A potent immunotherapeutic approach for hepatocellular carcinoma.

• Authors : Hou K; Clinical Research Center of the Second Affiliated Hospital, University of South China, Hengyang, Hunan, PR China.; Xu X

Subjects: Carcinoma, Hepatocellular*/Carcinoma, Hepatocellular*/Carcinoma, Hepatocellular*/immunology ; Carcinoma, Hepatocellular*/Carcinoma, Hepatocellular*/Carcinoma, Hepatocellular*/therapy ; Immunotherapy*/Immunotherapy*/Immunotherapy*/methods

• Source: BioFactors (Oxford, England) [Biofactors] 2024 Mar-Apr; Vol. 50 (2), pp. 250-265. Date of Electronic Publication: 2023 Nov 03.Publisher: Ios Press Country of Publication: Netherlands NLM ID: 8807441 Publication Model: Print-Electronic Cited Medium:

Record details

Immune Checkpoint Inhibitors in Metastatic Bladder and Other Solid Malignancies: How Long is Enough?

• Authors : Kumar V; Brigham and Women's Hospital, Boston, MA, USA.; Wei XX

• Source: Bladder cancer (Amsterdam, Netherlands) [Bladder Cancer] 2023 Sep 25; Vol. 9 (3), pp. 201-210. Date of Electronic Publication: 2023 Sep 25 (Print Publication: 2023).Publisher: IOS Press Country of Publication: Netherlands NLM ID: 101668567 Publication Model: eCollection Cited Medium:

Record details

PD-1 inhibitor combined with Docetaxel exerts synergistic anti-prostate cancer effect in mice by down-regulating the expression of PI3K/AKT/NFKB-P65/PD-L1 signaling pathway.

• Authors : Zhou, Sixu; Wang, Baogui; Wei, Yingying

Subjects: PROSTATE cancer; DOCETAXEL; PROGRAMMED cell death 1 receptors

• Source: Cancer Biomarkers; 2024, Vol. 40 Issue 1, p47-59, 13p

Record details

Comparing modeling strategies combining changes in multiple serum tumor biomarkers for early prediction of immunotherapy non-response in non-small cell lung cancer.

• Authors : van Delft, Frederik A.; Schuurbiers, Milou M.F.; Muller, Mirte

Subjects: TUMOR markers; NON-small-cell lung carcinoma; IMMUNE checkpoint inhibitors

• Source: Tumor Biology (IOS Press); 2024 Supplement, Vol. 46, pS269-S281, 13p

Record details

Effects of PD-1/PD-L1 signaling pathway on intestinal flora in patients with colorectal cancer.

• Authors : Pi H; Department of Laboratory Medicine, Dongguan Eastern Central Hospital, Dongguan, Guangdong, China.; Huang L

Subjects: Colorectal Neoplasms/Colorectal Neoplasms/Colorectal Neoplasms/*drug therapy ; Gastrointestinal Microbiome/Gastrointestinal Microbiome/Gastrointestinal Microbiome/*immunology ; Immune Checkpoint Inhibitors/Immune Checkpoint Inhibitors/Immune Checkpoint Inhibitors/*pharmacology

• Source: Cancer biomarkers : section A of Disease markers [Cancer Biomark] 2020; Vol. 28 (4), pp. 529-535.Publisher: IOS Press Country of Publication: Netherlands NLM ID: 101256509 Publication Model: Print Cited Medium:

Record details

PD-1/PD-L1 pathway: Current research in breast cancer.

• Authors : Syamsu SA; Division of Oncology, Department of Surgery, Faculty of Medicine, Hasanuddin University, Makassar, Indonesia.; Faruk M

Subjects: Breast Neoplasms*/Breast Neoplasms*/Breast Neoplasms*/immunology ; B7-H1 Antigen* ; Programmed Cell Death 1 Receptor*

• Source: Breast disease [Breast Dis] 2024; Vol. 43 (1), pp. 79-92.Publisher: IOS Press Country of Publication: Netherlands NLM ID: 8801277 Publication Model: Print Cited Medium: Internet

Record details

Analysis of clinical efficacy and long-term prognosis of patients with hepatocellular carcinoma treated with PD-L1 inhibitor targeting.

• Authors : Si T; Guo Y; Yang M

Subjects: Carcinoma, Hepatocellular*/Carcinoma, Hepatocellular*/Carcinoma, Hepatocellular*/drug therapy ; Liver Neoplasms*/Liver Neoplasms*/Liver Neoplasms*/drug therapy; Humans

• Source: Technology and health care : official journal of the European Society for Engineering and Medicine [Technol Health Care] 2024; Vol. 32 (5), pp. 3189-3200.Publisher: IOS Press Country of Publication: Netherlands NLM ID: 9314590 Publication Model: Print Cited Medium: Internet

Record details

CYFRA 21-1, CA 125 and CEA provide additional prognostic value in NSCLC patients with stable disease at first CT scan.

• Authors : Muley, Thomas; Schneider, Mark A.; Meister, Michael

Subjects: COMPUTED tomography; PROGNOSIS; NON-small-cell lung carcinoma

• Source: Tumor Biology (IOS Press); 2024 Supplement, Vol. 46, pS163-S175, 13p

Record details